Background: Anti-Tumor Necrosis Factor (TNF)-α therapy seems to improve vascular pathology in patients with inflammatory arthropathies such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Asymmetric dimethylarginine (ADMA) competes with Larginine as a substrate for nitric oxide synthase (NOS) and the L-arginine/ADMA ratio is important for modulation of the NOS activ...

POLSKIE ARCHIWUM MEDYCYNY WEWNĘTRZNEJ 2013; 123 (10) To the Editor We read the article by Szpak et al.1 with interest. The authors investigated whether active or passive tobacco smoking may affect en‐ dothelial dysfunction markers such as asymme‐ tric dimethylarginine (ADMA), thrombomodulin (TM), plasminogen activator inhibitor‐1 (PAI‐1), and cotinine levels in patients with advanced co‐ ronary...

Asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), impairs the beneficial effect of NO. The predictive value of ADMA for all-cause mortality remains controversial, though it is important in the development of cardiovascular disease (CVD) and progression to dialysis in renal disease. This systematic review and meta-analysis was conducted to investigate ...

Date of acceptance / Kabul tarihi: December 5, 2016 / 5 Aralık 2016 ABSTRACT: Is there a correlation between plasma levels of asymmetric dimethylarginine (ADMA) levels and atherosclerosis in type 2 diabetes patients in Turkey? Objective: Atherosclerosis is very common in patients with diabetes mellitus (DM). We aimed to investigate the relationship between asymmetric dimethylarginine (ADMA) whi...

BACKGROUND The pathophysiology of cardiac syndrome X is multifactorial and endothelial dysfunction has been implicated as important contributing factor. Asymmetric dimethylarginine (ADMA), characterized as a circulating endogenous inhibitor of nitric oxide synthase, may have been implicated as an important contributing factor for the development of endothelial dysfunction. In this study, we aim...

Asymmetrical dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor. It is formed by protein arginine N-methyltransferases (PRMTs), which utilize S-adenosylmethionine as methyl group donor. ADMA plasma concentration is elevated in hypercholesterolemia, leading to endothelial dysfunction and producing proatherogenic changes of endothelial cell function. Four different isoforms ...

Metformin and asymmetric dimethylarginine (ADMA) are structural analogs. They have opposite effects at multiple points on complex signaling pathways that coordinate energy, molecular synthesis, growth, and metabolism with nutrient intake. Excess saturated fats and glucose may initiate the methylation of arginine residues in proteins involved in the transcription of genes mediating inflammation,...

Introduction Chronic kidney disease is a major public health problem. In the last decade, it has been shown that the early stages of chronic kidney disease are associated with an inflammatory condition involving an increased risk of cardiovascular morbidity and long-term mortality. In patients with chronic kidney disease and more specifically those on hemodialysis, cardiovascular events are the...

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) produced by epithelial and inflammatory cells are key mediators of the chronic airway inflammation of asthma. Low L-arginine levels can result in the uncoupling of nitric oxide synthase (NOS) leading to production of both ROS and RNS. Asymmetric dimethylarginine (ADMA) is a competitive endogenous inhibitor of all NOS isoforms and...